Health 360x brings together patients, clinicians, and researchers to enhance the health of neglected groups. Health 360x is changing clinical research through point-of-care access for patients and providers in non-academic practices that mostly serve African Americans and other patients who have historically been underrepresented in corporate and NIH clinical trials.
National Disease Research Interchange is the source of human tissues, cells and organs for scientific research.
Pulvinar Neuro is to enable and support outstanding basic and translational neuroscience research through innovative and affordable products.
A leader in medical research, teaching and patient care, Washington University School of Medicine is currently ranked fourth in the nation by U.S. News & World Report. The School’s 2,100 employed and volunteer faculty physicians and clinicians -- known as Washington University Physicians -- are also medical staff members of Barnes-Jewish and St. Louis Children’s hospitals. The clinical practice group provides care to more than 430,000 children and adults at 49 clinical sites annually. Together, the institutions located on the Washington University Medical Center campus employ more than 21,000 clinicians, scientists, residents, fellows, administrators and support staff.
Rice University is a private research institution located in Houston, Texas, founded in 1912 through the bequest of businessman William Marsh Rice. It emphasizes undergraduate education and is organized into eleven residential colleges and eight academic schools, including the Wiess School of Natural Sciences and the George R. Brown School of Engineering. The university offers graduate programs in various fields, including business, architecture, and music. Known for its rigorous Honor Code, which is enforced by a student-run Honor Council, Rice is recognized for its strong research capabilities, particularly in applied sciences such as artificial heart research and nanotechnology. Additionally, Rice has been acknowledged for its entrepreneurial initiatives and ranks highly among global business incubators. With a diverse student body of approximately 3,900 undergraduates and 2,600 graduate students from numerous countries, Rice University is a member of the Association of American Universities, fostering an inclusive and intellectually vibrant community.
Sapphiros is a private equity growth and expansion firm based in Massachusetts, founded in 2021. The firm focuses on investing in growth-stage companies that are engaged in innovative and patient-centric diagnostic technologies. By supporting the next generation of diagnostics, Sapphiros aims to bridge the gap between current practices and future advancements in the healthcare sector.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in discovery, development, and commercialization of a pipeline of microRNA (miRNAs) therapeutics for treating metastatic disease. It develops a platform of targeted therapies that relies on specific eradication of metastatic tumor cells through pharmacological inhibition of microRNA-10b. The company was founded n 2016 and is based in Boston, Massachusetts.
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Second Sight Medical Products, Inc. is a company that specializes in the development, manufacturing, and marketing of implantable visual prosthetics aimed at providing artificial vision to blind individuals. Founded in 1998 and headquartered in Sylmar, California, the company offers innovative technologies designed to assist those with various causes of blindness, including glaucoma, diabetic retinopathy, optic nerve injuries, and retinitis pigmentosa. Its primary products include the Orion Visual Cortical Prosthesis System, which stimulates the cortex to deliver useful artificial vision, and the Argus II Retinal Prosthesis System, designed specifically for patients with outer retinal degenerations. Through its commitment to advancing medical technology, Second Sight seeks to enhance the independence and quality of life for individuals affected by blindness.
CardieX is a global health technology company focused on cardiovascular health management, particularly in hypertension and related vascular disorders. The company designs, manufactures, and markets medical devices that assess patient risk for these conditions, utilizing its patented SphygmoCor technology to measure arterial stiffness and central blood pressure waveforms. In addition to medical devices, CardieX offers TeleHealth Services, providing digital and mobile tools for patients to connect with health coaches. The company's products and services are targeted at hospitals, clinics, research institutions, and pharmaceutical companies across the Americas, Europe, and the Asia Pacific. CardieX also engages in strategic collaborations, including a partnership with Blumio Inc. to develop wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. Founded in 1994 and headquartered in Sydney, Australia, CardieX was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.
The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.
Medcognetics enables radiologists to control their workflow, and the offered solution improves efficiency and accuracy. Mammography patients can be prioritized by radiologists based on questionable results. They reduce breast cancer mortality by finding the disease as early as possible.
Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.
The Albert Einstein College of Medicine of Yeshiva University is a premier, research-intensive medical school dedicated to innovative biomedical investigation and to the development of ethical and compassionate physicians and scientists. Inspired by the words of our namesake, we welcome students, faculty and staff from diverse backgrounds who strive to enhance human health in the community and beyond.
The John A. Burns School of Medicine at the University of Hawaii at Mānoa is one of the leading medical schools in the United States.
Worcester Polytechnic Institute (WPI), founded in 1865, is a non-profit educational institution located in the United States. It provides a diverse range of undergraduate and graduate programs, including fields such as computer science, chemical engineering, psychology, and business administration. WPI is known for its distinguished faculty, advanced research facilities, and an active community that fosters collaboration and innovation. The institute emphasizes a hands-on approach to learning, encouraging students to engage in real-world problem-solving and make meaningful contributions to society.
iQure Pharma is a global biotech company created by entrepreneurs and former pharma managers that focuses on the development of new therapeutics.
The University of Kentucky, founded in 1865, is a public, non-profit institution and Kentucky's flagship university. It is dedicated to enhancing lives through high-quality education, research, and service, with a strong emphasis on health care. The university offers a range of graduate and undergraduate programs, particularly in agriculture and mechanical fields. As a land grant institution, it assumes a vital leadership role in promoting diversity, inclusion, economic development, and overall human well-being within the community and beyond.
RAE Health is a mental health solutions company focused on addressing substance use disorders through innovative technology. The company develops monitoring systems that empower patients by actively engaging them in their recovery process. Its technology is designed to identify, detect, and track patterns related to cravings, stress, and drug use, facilitating timely interventions from healthcare providers. By bridging the gap between mobile health and digital therapeutics, RAE Health aims to enhance patient outcomes, save lives, and reduce relapse rates among individuals struggling with addiction.
Second Sight Medical Products, Inc. is a company that specializes in the development, manufacturing, and marketing of implantable visual prosthetics aimed at providing artificial vision to blind individuals. Founded in 1998 and headquartered in Sylmar, California, the company offers innovative technologies designed to assist those with various causes of blindness, including glaucoma, diabetic retinopathy, optic nerve injuries, and retinitis pigmentosa. Its primary products include the Orion Visual Cortical Prosthesis System, which stimulates the cortex to deliver useful artificial vision, and the Argus II Retinal Prosthesis System, designed specifically for patients with outer retinal degenerations. Through its commitment to advancing medical technology, Second Sight seeks to enhance the independence and quality of life for individuals affected by blindness.
Lewis Katz School of Medicine is dedicated to excellence in education, research and patient care, achieved by faculty, staff and learners who represent and serve their diverse society.
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.
Burke Neurological Institute is the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord.
Cleveland Clinic is a non-profit academic medical center established in 1921 and headquartered in Cleveland, Ohio. It integrates clinical and hospital care with research and education, focusing on improving patient care, investigating medical issues, and educating healthcare providers. As a pioneer in healthcare, Cleveland Clinic became the first U.S. healthcare provider to sign the United Nations Global Compact in 2008. Its commercialization arm, Cleveland Clinic Innovations, transforms breakthrough inventions from its staff into medical products that benefit patients. This initiative fosters an inclusive environment for innovation, enabling participation from various stakeholders such as physicians, nurses, and researchers. Cleveland Clinic Innovations employs a comprehensive strategy that includes deal teams, domain experts, investment funds, and incubation facilities to support the development of new medical technologies and stimulate economic growth in Northeast Ohio and beyond.
OMRF is the Oklahoma Medical Research Foundation. We are dedicated to fighting Alzheimer’s, heart disease, lupus, MS, cancer and other devastating illnesses.
Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.
Immunicom, Inc. is a clinical research company based in San Diego, California, founded in 2013. The company focuses on innovative, non-pharmaceutical approaches to immunotherapy, specifically targeting cancer, inflammatory diseases, and autoimmune disorders. Its flagship product is a therapeutic blood-filtering device designed to treat various types of cancer, including those resistant to traditional treatments. This device aims to enhance the effectiveness of existing cancer therapies while potentially reducing side effects, thus providing physicians with a new tool to directly combat cancer. By redefining the boundaries of immunotherapy, Immunicom seeks to improve treatment options for patients with terminal diseases.
AVM Biotechnology LLC is a regenerative medicine company focused on the discovery, development, and commercialization of stem cell technologies for applications in regenerative medicine, oncology, and human biologics. Founded in 2008 by Dr. Theresa Deisher, the company offers a range of innovative compounds aimed at enhancing organ regeneration and immune recovery through the modulation of stem cell binding. AVM Biotechnology has developed personalized medicine solutions via its Boutique Biologics platform, which produces patient-specific biologics to minimize immunogenicity and improve therapeutic efficacy. It also features the Better Biologics platform for large-scale production of human biologics, addressing resistance issues associated with non-human cell systems. The company is advancing several products in preclinical stages, including its lead candidate AVM0703, which has received FDA IND approval for treating lymphoid malignancies and may also be effective against COVID-19 and influenza. AVM Biotechnology is committed to transforming treatment outcomes for cancer, autoimmune disorders, and chronic infectious diseases through its specialized biotechnology platform.
Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians.
Talus Bio is a biotechnology startup specializing in drug discovery, particularly in the field of oncology. The company has developed a data-enabled platform that integrates cell processing with high-sensitivity quantitative proteomics and machine learning analytics. This innovative approach allows for the study of gene regulatory proteins within living cells, facilitating targeted small molecule drug development. By focusing on the mechanisms of gene regulation, Talus Bio aims to enhance drug development processes for clients in the healthcare sector, ultimately advancing therapies for cancer treatment.
NovoMedix is a biotechnology company focused on developing novel orally available small molecules aimed at treating fibrotic disorders and certain cancers, particularly triple negative breast cancer (TNBC). The company’s innovative compounds demonstrate significant efficacy in animal models for fibrosis and possess unique properties that offer cardioprotective effects in conjunction with standard chemotherapy treatments. This is especially relevant for TNBC patients who often experience delayed cardiomyopathy as a result of anthracycline treatments, which can lead to cardiovascular disease being a leading cause of death among breast cancer survivors. By co-targeting pathways involved in both cancer treatment and heart protection, NovoMedix aims to enhance patient responses to therapy while significantly reducing the risk of cardiotoxicity. The company is preparing to initiate IND enabling studies for its lead candidate, with the goal of delivering this promising therapy to TNBC patients as quickly as possible.
Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology for surgical patients. The company's primary focus is on developing an ultrasound-based method to detect anastomotic blood clots, which are critical for patient recovery post-surgery. By providing clinicians with real-time visualization of essential data directly at the point of care, Sonavex aims to enhance clinical decision-making and improve patient outcomes. Their proprietary technology platform allows for the measurement of crucial intravascular flow metrics, enabling the early detection of post-operative clots and contributing to better overall surgical results.
Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.
PostEra is a company based in Santa Clara, California, that specializes in medicinal chemistry services by combining molecular design with chemical synthesis. Founded in 2019, it leverages machine learning algorithms to streamline the drug discovery process, significantly reducing cycle times for its clients. The platform automates traditional manual methods, allowing for the iterative refinement of drug candidates, prediction of manufacturing techniques, and optimization of experimental testing. By addressing challenges in chemical reaction predictions and bioactivity assessments, PostEra aims to enhance the efficiency and safety of drug development. The company is actively involved in an international initiative to discover antiviral treatments for COVID-19 through open science collaboration.
As Razorback nation’s medical campus, the University of Arkansas for Medical Sciences is a hub for medical treatment, research and academics. UAMS offers an impressive number of academic programs through its many divisions: * College of Medicine * College of Pharmacy * College of Nursing * College of Health Related Professions * College of Public Health * Graduate School As you can expect, a great number of programs are available through these schools and colleges. University of Arkansas for Medical Sciences offers undergraduate and graduate academics, ranging from certificates to master’s and doctoral degrees. With such exhaustive academics comes equally extensive research. Some research opportunities at University of Arkansas for Medical Sciences are more straightforward, while others are quite unusual. For example, students in the Psychiatric Research Institute were recently able to enrich college life by talking to actors in the Arkansas Repertory Theatre. Admissions requirements at University of Arkansas for Medical Sciences are very program-specific. The admissions process is handled through the individual college you’re applying to, so procedures and requirements may vary. This applies to financial aid, as well; so make sure to consult University of Arkansas for Medical Sciences for specific information.
Benaroya Research Institute at Virginia Mason (BRI) is one of the few research institutes in the world dedicated to discovering causes and cures to eliminate autoimmune and immune system diseases. At BRI, their scientists aren’t focused on eliminating one or two autoimmune diseases—they’re taking on all 80. Because autoimmune diseases are connected, so is the way they’re fighting them. They're applying the breakthroughs they make against individual autoimmune diseases to make progress against them all. Through collaboration and cooperation between researchers, across clinical trials and with other institutions, they connect laboratory research to clinical trials and translate discoveries to real-life applications. As a world leader in scientific innovation, they’re leveraging this progress to eliminate autoimmune and immune system diseases in the future. Their discoveries are also having significant impact on people living with autoimmune and immune system diseases today—by improving the ability to predict disease risk, facilitate treatment, decrease progression of these diseases and make related therapies safer and more effective.
The University of Texas Health Science Center at San Antonio serves San Antonio and the 50,000 square-mile area of South Texas. It extends to campuses in the metropolitan border communities of Laredo and the Rio Grande Valley. More than 3,000 students a year train in an environment that involves more than 100 affiliated hospitals, clinics and health care facilities in South Texas. The UT Health Science Center and its Cancer Therapy & Research Center hold diversity as a core value. In this context, they are mindful of all aspects of human differences, such as socioeconomic status, race, ethnicity, language, nationality, sex, gender identity, sexual orientation, religion, geography, disability and age. At the UT Health Science Center and CTRC, inclusion is a core element for successfully achieving diversity, as they strive to create a climate that fosters belonging, respect and value for all. As an equal employment opportunity and affirmative action employer, the UT Health Science Center and CTRC exercise these core values of diversity and inclusion by promoting and ensuring equal employment opportunity for all individuals without regard to race, color, religion, sex, national origin, age, sexual orientation, disability, or veteran status.
The Albert Einstein College of Medicine of Yeshiva University is a premier, research-intensive medical school dedicated to innovative biomedical investigation and to the development of ethical and compassionate physicians and scientists. Inspired by the words of our namesake, we welcome students, faculty and staff from diverse backgrounds who strive to enhance human health in the community and beyond.
Coprata Inc. focuses on non-invasive physiological monitoring through innovative technology that allows for discreet health tracking with minimal disruption to daily life. The company is developing a Smart Sampling Toilet, a novel wastewater technology licensed from Duke University, which was created by researchers associated with the Bill and Melinda Gates Foundation. This digital health platform aims to facilitate hands-free stool sampling and automate the monitoring of bowel movements, enabling the detection and management of both acute and chronic gastrointestinal diseases. Additionally, it provides early warnings for infectious diseases, helping individuals access tools for personalized wellness monitoring.
Simulations Plus, Inc. is a developer of software solutions for drug discovery and development, specializing in mechanistic modeling and simulation. The company offers a range of products, including GastroPlus for simulating pharmacokinetics and drug interactions, DDDPlus for in vitro laboratory experiment simulations, and ADMET Predictor for predicting molecular properties. Additional offerings include KIWI, a cloud-based application for managing data in drug development, and specialized software for various diseases and conditions such as DILIsym and NAFLDsym. Established in 1996 and headquartered in Lancaster, California, Simulations Plus serves a diverse client base, including pharmaceutical and biotechnology companies, agrochemical and cosmetic industries, and regulatory agencies. The company also provides consulting and contract research services, enhancing its role in the pharmaceutical industry by enabling clients to make informed decisions and reduce research and development costs.
Dascena, Inc. is a technology company based in Oakland, California, specializing in the development of algorithm software for diagnostics and biomarkers. Founded in 2018, Dascena creates machine learning algorithms designed to enhance early disease intervention and improve patient care outcomes. Its primary product, AlgoDiagnostics, autonomously processes electronic health record data to identify conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging advanced algorithms, Dascena aims to facilitate timely medical responses and support healthcare professionals in delivering better patient care.
Operator of a clinical research firm intended to develop applications using machine learning and natural language processing for the healthcare and life sciences industries. The company's services provide detailed patient information for clinical research and medical practice, normalize and standardize complex clinical data to unified representations using clinical ontologies, conduct medical coding and identify drug side effects and drug-drug interactions, enabling health enterprises and large-scale hospitals to collect and analyze data for healthcare service quality and patient safety.
Developer of next-generation sequencing tools and software solutions designed to allow fast, precise and cost-effective analysis. The company's offering includes antimicrobial resistance (AMR) detection software solutions to automate the detection of both pathogen and antimicrobial resistance gene sequences while simultaneously aligning sequence across multiples species and gene sequences, enabling clients to obtain a fast and accurate annotation for any gram-negative bacterial DNA sequence in less than five minutes.
NYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one of the nation's premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals – Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology; and Hassenfeld Children’s Hospital, a comprehensive pediatric hospital supporting a full array of children's health services across the medical center – plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The medical center's tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research.
Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and research. Founded in 2014, it provides a suite of diagnostic and discovery software that enables physicians, pharmaceutical companies, and researchers to quickly and accurately identify disease-causing variants from genomic-sequencing datasets. The flagship product, GENOMENON, automates the analysis of next-generation sequencing data, facilitating faster decision-making in cancer diagnosis and treatment, as well as in the study of inheritable diseases. By improving the efficiency of genomic interpretation, Genomenon aims to enhance patient outcomes and advance genetic research.
Meridian Bioscience, Inc. is an integrated life science company focused on the development, manufacturing, and distribution of clinical diagnostic test kits for various infectious diseases, including gastrointestinal, viral, respiratory, and parasitic conditions. The company specializes in molecular and immunological reagents used in diagnostic applications, catering to healthcare professionals with products that assist in the discovery and diagnosis of medical conditions. In addition to diagnostic kits, Meridian manufactures and distributes bulk antigens, antibodies, PCR and qPCR reagents, and other bioresearch reagents utilized by researchers and diagnostic manufacturers. Furthermore, the company engages in contract development and manufacturing of proteins and biologicals under cGMP conditions for biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science.
Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and Alzheimer's disease. Established in 2013, the company has made significant scientific advancements in the field of biologic therapeutics, particularly targeting Low-Density Lipoprotein Receptors (LDLRs) to facilitate the repair of neurological damage. Novoron is advancing a pipeline of pre-clinical therapies aimed at enhancing recovery from CNS-related conditions, thereby improving the quality of life for affected patients. As a member of the JLABS innovation community, the company continues to explore novel therapeutic approaches to address these complex medical challenges.
Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.
FAU - College of Engineering and Computer Science is an academic college of Florida Atlantic University. It encompasses three academic departments and nine technical disciplines and offers 20 degree programs. The courses offered are presented on-campus, off-campus, and through distance learning in bioengineering, civil engineering, computer engineering, computer science, electrical engineering, geomatics engineering, mechanical engineering, and ocean engineering. FAU - College of Engineering and Computer Science was founded in 1965.
Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
Penn Medicine, someone will make a breakthrough. Someone will heal a heart, deliver hopeful news, give comfort and reassurance. Today, a Penn physician, scientist, nurse, technician or social worker will find another way to heal or help, unlock medical science that can give the gift of more time and change the course of human life.
Bleep provides best new CPAP solution on the market. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That’s why they invented the DreamPort Sleep Solution – the world’s first-ever mask less CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn’t restrict your movement – enabling patients to get a better night’s sleep. Their goal is simple – to make the best bleeping CPAP products on the planet. They won’t stop until every sleep apnea patient is sleeping like a baby.
Delpor, Inc. develops innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant device. Its key technologies include Prozor, designed for delivering antipsychotics and other small molecule drugs; NANOPOR, which provides sustained release through specialized membrane architecture; and Delos PUMP, a self-contained device that enables drug delivery in predetermined patterns, particularly beneficial for medications requiring pulsed administration, such as fertility hormones and pain medications. Established in 2009, Delpor is headquartered in San Francisco, California.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
Developer of novel therapeutics designed to treat chronic pain disorders, such as neuropathic pain. The company specializes in orally-bioavailable MNK inhibitors with improved tissue-specificity and pharmacokinetic profiles that have potent analgesic activity in multiple animal pain models, enabling doctors to use the drugs for targeting the activity of the elF4E proteins to regulate the activity of pain-sensing neurons in the peripheral nervous system.
Anavasi Diagnostics is a medical technology company specializing in molecular diagnostic testing. The company has developed a clinical diagnostic platform that enables rapid diagnosis of COVID-19 in patients. This platform is designed for use in point-of-care settings, utilizing proprietary test kits for molecular analysis of patient samples. By providing medical personnel with an accessible and cost-effective device, Anavasi Diagnostics facilitates early detection and subsequent diagnosis of COVID-19, enhancing the ability to respond swiftly to the pandemic.
Arkansas Children's Hospital is the only pediatric medical center in Arkansas and ranks among the largest in the United States. Covering 29 city blocks, the facility contains 370 beds and employs around 500 physicians, along with 80 pediatric residents and over 4,400 staff members. As a private, nonprofit organization, it has gained an international reputation for its medical innovations, specialized treatments, and groundbreaking research, all aimed at improving children's health and development. Additionally, the Arkansas Children's Research Institute operates under the umbrella of Arkansas Children's, Inc., further supporting its mission. The hospital has been recognized for its workplace culture, appearing on the FORTUNE 100 Best Companies to Work For list for three consecutive years, most recently achieving the 75th position.
Tuskegee University in Tuskegee, Alabama, is a historically black university (HBCU) of academic excellence and innovation. Tuskegee distinguishes itself by offering programs of study not found at any other historically black university. Tuskegee also graduates a majority of the nation’s successful African American scientists and engineers. Tuskegee’s programs of study are offered through several distinctive colleges. These include the colleges of: * Architecture and Construction Science * Arts and Sciences * Business and Information Science * Education Tuskegee is also one of the only African American institutions that offers a degree in veterinary science. Consequently, the majority of the world’s African American veterinarians graduated from Tuskegee. Tuskegee also produces many of the nation’s aerospace, chemical and electrical engineers. While Tuskegee is historically black, the school welcomes students of all backgrounds. Required admissions materials include an application, which applicants can download from the website, transcripts and ACT or SAT scores. Tuskegee awards several competitive, academic scholarships. Tuskegee awards these to students with an exceptional GPA and test scores. Tuskegee students may also apply for federal financial aid. Federal aid is given on the basis of financial need and includes grants and loans. To apply for federal aid, applicants must submit a FAFSA.
Michigan State University, founded in 1855 and located in East Lansing, Michigan, is a comprehensive educational institution offering a wide range of undergraduate, graduate, and research programs across various fields, including business, humanities, science and technology, and public affairs. Its academic structure comprises several colleges, including the Eli Broad College of Business and the Eli Broad Graduate School of Management, among others. In addition to its educational mission, Michigan State University manages an endowment fund with $200 million in assets, employing alternative investment strategies such as buyouts, hedge funds, and venture capital. The endowment aims for a net internal rate of return of 10%, with allocations of up to 11% of total assets dedicated to alternative investments. This fund has been operational since 1988, highlighting the university's commitment to financial stewardship in support of its educational objectives.
Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Chosen Diagnostics specializes in developing innovative biomarker diagnostic kits aimed at enhancing healthcare delivery for neonates. The company’s primary product is a test designed to diagnose a serious and potentially life-threatening bowel disease in preterm infants. This diagnostic kit provides more accurate results compared to existing methods, facilitating earlier medical intervention. By enabling timely detection of critical health issues, Chosen Diagnostics aims to improve treatment outcomes for thousands of low birth weight preterm infants, ultimately leading to better healthcare results in this vulnerable population.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
Drexel University, founded in 1891 and located in Philadelphia, is a prominent global research institution with approximately 26,000 students, ranking among the top 100 universities in the United States. Recognized for its leadership in experiential learning, particularly through its Co-op program, Drexel is also noted for its pioneering work in academic technology and translational research. The university operates multiple campuses in Philadelphia and engages in international research partnerships, enhancing its global presence. Drexel is one of the largest private universities in the nation and a major economic driver in the Philadelphia region, where it ranks among the top employers. The university is committed to civic engagement, integrating community partnerships into its academic and service initiatives. Additionally, Drexel’s endowment fund supports scholarships and various university operations, with investment strategies focused on diverse asset classes, ensuring financial stability and academic excellence.
Florida State University (FSU) is a distinguished institution located in the heart of Florida's capital, known for its rich heritage and commitment to academic excellence. As the oldest continuous site of higher education in Florida, FSU offers a diverse range of programs through its 16 colleges, encompassing over 275 undergraduate, graduate, doctoral, professional, and specialist degrees. The university is recognized for its strong emphasis on the arts and humanities, as well as its leadership in the sciences, particularly through research opportunities at the National High Magnetic Field Laboratory, the only national lab in the state. Each year, FSU awards more than 2,000 graduate and professional degrees, contributing to a global network of over 300,000 alumni. With nationally-ranked academics and championship athletics, FSU provides a vibrant and supportive environment for students, fostering their potential to achieve extraordinary outcomes.
Provider of technology consulting services intended to offer various computer programming services. The company's services include application development, management consulting, quality assurance, and research and development services, enabling organizations in utilizing the proven system integration methodologies and expertise as their backbone in delivering value-driven business solutions.
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Operator of a life science platform intended for democratizing advanced single-cell assays. The company's novel nano vial platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, enabling biotech labs and clients to develop higher-performing therapies for cancer, autoimmune conditions, and infectious diseases.
Autonomous Healthcare’s mission is to reduce intensive care unit morbidity and mortality through automation.
Arkansas Children's Hospital is the only pediatric medical center in Arkansas and ranks among the largest in the United States. Covering 29 city blocks, the facility contains 370 beds and employs around 500 physicians, along with 80 pediatric residents and over 4,400 staff members. As a private, nonprofit organization, it has gained an international reputation for its medical innovations, specialized treatments, and groundbreaking research, all aimed at improving children's health and development. Additionally, the Arkansas Children's Research Institute operates under the umbrella of Arkansas Children's, Inc., further supporting its mission. The hospital has been recognized for its workplace culture, appearing on the FORTUNE 100 Best Companies to Work For list for three consecutive years, most recently achieving the 75th position.
Our products improve the sleep quality and make the nighttime safe by responding to the personalized needs of individuals. Our smart mattress, combined with our software, is designed to provide sleep therapy and improve medical care that is beneficial for wellness, emergency assistance, and health monitoring both at home and in the hospital.
Amydis, Inc. is a privately-held pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins. Our mission is to develop a universal, non-invasive diagnostic that is faster, more accessible, and more affordable than current tests for diseases with unmet clinical and medical needs. Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling diagnosis of such diseases. The Company’s most advanced program is targeting the detection of early stage Alzheimer’s disease, a well-known amyloid disease. Other potential development programs include the detection of Parkinson’s disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy, all of which are associated with the presence of amyloid protein. Amydis offers you and your loved ones the ability to know whether you are at risk for Alzheimer’s or other amyloid-associated diseases. Knowing will allow you and your healthcare professional to make the right decisions.
Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
ImmunoBrain Checkpoint, Inc. is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz (Weizmann Institute of Science, Israel).
Eclipse Regenesis is a development-stage medical device company dedicated to harnessing the body’s natural tissue regeneration capabilities to treat significant diseases. The company's flagship product, the Eclipse XL1 System, employs distraction enterogenesis to mechanically stimulate the body to generate new, fully functional intestinal tissue, specifically targeting Short Bowel Syndrome (SBS). With over 15 years of scientific research backing its approach, Eclipse Regenesis collaborates with SBS experts worldwide to pioneer restorative therapies for this currently incurable condition. The Eclipse XL1 System remains an investigational device and is not yet available for commercial use in any region.
Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems.
CareKinesis, Inc. provides state-of-the-art medication management through a combination of technology, science and services that reduces costs, improves the quality of care and decreases the risks associated with ineffective medication plans.
ID Genomics is focused on nucleotide sequence-based molecular diagnostics and epidemiological analysis of microbial pathogens. The company offers high-resolution clonal identification suitable for both large and small-scale applications in clinical microbiology, reference, and academic research laboratories. Utilizing expanded multi-locus sequence typing (MLST) and genome-wide polymorphism annotation, ID Genomics provides customized phylogenetic and genomic analyses, along with database creation. Their diagnostic system integrates molecular diagnostics with epidemiological surveillance and big data tools, enabling rapid matching of infecting pathogens to appropriate treatments. This approach allows healthcare providers to make informed antibiotic choices quickly, enhancing personalized treatment for infectious diseases and ultimately improving patient outcomes.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in discovery, development, and commercialization of a pipeline of microRNA (miRNAs) therapeutics for treating metastatic disease. It develops a platform of targeted therapies that relies on specific eradication of metastatic tumor cells through pharmacological inhibition of microRNA-10b. The company was founded n 2016 and is based in Boston, Massachusetts.
Praxis Bioresearch is a privately-held biopharmaceutical company focused on the discovery and development of innovative prodrug stimulants aimed at treating various chronic neuropsychiatric and neurodegenerative disorders. The company's lead candidate, PRX-P4-003, is designed to provide the therapeutic benefits associated with existing stimulant medications while minimizing the risk of intravenous abuse. Through its research and development efforts, Praxis Bioresearch seeks to address unmet medical needs in the management of these complex conditions.
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Cytonus Therapeutics is a biotechnology company focused on developing innovative immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Established in 2018 and based in Columbus, Ohio, the company has created a proprietary platform utilizing Cargocyte technologies—advanced biomolecular delivery systems designed to transport therapeutic agents effectively to hard-to-reach tissues. By combining artificial intelligence-driven drug discovery with synthetic biology, Cytonus aims to provide precision delivery of therapeutics for a variety of medical conditions, including cancers, infectious diseases, inflammatory disorders, and cognitive issues. The technology allows for the selective and controlled delivery of allogeneic therapies, enhancing patient outcomes in areas of significant unmet medical need.
NeuroPace, Inc. specializes in the design, development, manufacturing, and marketing of implantable devices aimed at treating neurological disorders through responsive stimulation. The company's flagship product, the RNS System, is specifically designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers electrical pulses to targeted areas to prevent seizures. The RNS System comprises various components, such as depth leads and cortical strip leads for implantation, along with external devices like a programmer that allows healthcare professionals to communicate with the neurostimulator. Founded in 1997, NeuroPace is headquartered in Mountain View, California.
HelixBind is a Massachusetts-based company that operates in the biotechnology sector. The company was founded in 2012 and is based in Worcester, Massachusetts.
Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.
Operator of a life science platform intended for democratizing advanced single-cell assays. The company's novel nano vial platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, enabling biotech labs and clients to develop higher-performing therapies for cancer, autoimmune conditions, and infectious diseases.
Manufacturer of microscopy toolset intended to capture cellular-level detail over hundreds of square centimeters. The company's microscope uses custom-designed control electronics to deliver and process massive amounts of image data from a large array of micro-cameras, enabling companies to capture, analyze, and securely store tens of gigapixels of object-specific data with high throughput and improved analysis.
AvantGen is a biotechnology company based in San Diego, established in 2006, that specializes in therapeutic antibody discovery and optimization. The company operates two divisions: Therapeutic and Research & Diagnostic. Its Therapeutic Division focuses on the discovery of novel human antibodies, antibody humanization, and affinity maturation to enhance therapeutic development. AvantGen utilizes a proprietary yeast display system and maintains a large natural human antibody database, along with fully human antibody libraries and advanced screening technologies. The company's innovative platform also includes methodologies for rabbit monoclonal antibody generation and cell engager technology. AvantGen collaborates with pharmaceutical and biotechnology firms, offering services and licensing agreements to expedite the development of antibody-based therapeutics.
BiVACOR, Inc. is a privately held company based in Houston, Texas, that specializes in the design and manufacture of centrifugal heart pumps. Founded in 2008, BiVACOR employs a team of engineers, medical specialists, and business executives dedicated to advancing innovative cardiac technologies. The company has established a robust collaborative network that spans both national and international markets, with an additional office located in Brisbane, Australia. Through its commitment to developing cutting-edge solutions for heart pump technology, BiVACOR aims to improve patient outcomes in the field of cardiovascular health.
HDT Biotech Corporation, a biotechnology company, develops biotherapeutics for oncology and infectious disease applications. The company focuses on RNA, formulation, and adjuvant technologies. It develops RNA/LION that combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination. The company was founded in 2018 and is based in Seattle, Washington.